Persistent macular oedema following Best vitelliform macular dystrophy undergoing anti-VEGF treatment

doi:10.18240/ijo.2022.05.22

科研成果详情

题名	Persistent macular oedema following Best vitelliform macular dystrophy undergoing anti-VEGF treatment
作者	Tie-Zhu Lin ; Emmanuel Eric Pazo ; Yue Ren ; Li-Jun Shen
发表日期	2022-05-12
发表期刊	International Journal of Ophthalmology 影响因子和分区
语种	英语
原始文献类型	Journal Article
关键词	Persistent macular oedema following Best vitelliform macular dystrophy undergoing anti-VEGF treatment
摘要	Dear Editor,I am Dr. Tie-zhu Lin, from He Eye Specialist Hospital, Shenyang, China. I write to present the case of persistent macular oedema following Best vitelliform macular dystrophy(BVMD) undergoing anti-vascular endothelial growth factor(VEGF) treatment. BVMD also called Best's disease, is a hereditary disease due to mutation in the BEST1 gene located on chromosome 11~([1-2]) and has vastly variable phenotypic expression. During BVMD,
资助项目	Supported by Natural Science Foundation of Liaoning Province,China (No.2020-MS-360);; Shenyang Science and Technology Bureau (No.20-205-4-063)
ISSN	2222-3959
卷号	15 期号:05 页码:838-840
DOI	10.18240/ijo.2022.05.22
收录类别	CNKI ; PUBMED
URL	查看原文
PubMed ID	35601176
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/167731
专题	眼视光学院（生物医学工程学院）、附属眼视光医院
作者单位	1.Eye Hospital and School of Ophthalmology and Optometry, Wenzhou Medical University 2.He Eye Specialist Hospital 3.Ophthalmology Department, Zhejiang Provincial People's Hospital
推荐引用方式 GB/T 7714	Tie-Zhu Lin,Emmanuel Eric Pazo,Yue Ren,et al. Persistent macular oedema following Best vitelliform macular dystrophy undergoing anti-VEGF treatment[J]. International Journal of Ophthalmology,2022,15(05):838-840.
APA	Tie-Zhu Lin, Emmanuel Eric Pazo, Yue Ren, & Li-Jun Shen. (2022). Persistent macular oedema following Best vitelliform macular dystrophy undergoing anti-VEGF treatment. International Journal of Ophthalmology, 15(05), 838-840.
MLA	Tie-Zhu Lin,et al."Persistent macular oedema following Best vitelliform macular dystrophy undergoing anti-VEGF treatment".International Journal of Ophthalmology 15.05(2022):838-840.